GALE-301: Phase II started

Galena began an open-label, U.S. Phase II trial to evaluate GALE-301 plus GM-CSF in 30 HLA-A2-positive and 30 HLA-A2-negative patients with ovarian and endometrial cancer. Patients will receive an ini...